Blueprint Medicines Corp (BPMC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Blueprint Medicines Corp (BPMC) has a cash flow conversion efficiency ratio of -0.159x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.48 Million) by net assets ($342.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Blueprint Medicines Corp to measure how much of total assets are equity-financed.
Blueprint Medicines Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Blueprint Medicines Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Blueprint Medicines Corp (BPMC) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Blueprint Medicines Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Blueprint Medicines Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CTP N.V.
AS:CTPNV
|
0.016x |
|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
-0.213x |
|
Piraeus Financial Holdings S.A
AT:TPEIR
|
0.109x |
|
China Molybdenum Co. Ltd
F:D7N
|
0.041x |
|
Guangdong Fenghua Advanced Technology Holding Co Ltd
SHE:000636
|
0.007x |
|
Merlin Properties SOCIMI SA
LS:MRL
|
N/A |
|
Airtac International Group
TW:1590
|
0.040x |
|
Booz Allen Hamilton Holding
NYSE:BAH
|
0.217x |
Annual Cash Flow Conversion Efficiency for Blueprint Medicines Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of Blueprint Medicines Corp from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see BPMC market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $298.67 Million | $-192.59 Million | -0.645x | +80.72% |
| 2023-12-31 | $130.61 Million | $-436.85 Million | -3.345x | -242.73% |
| 2022-12-31 | $514.68 Million | $-502.28 Million | -0.976x | -217.21% |
| 2021-12-31 | $970.74 Million | $-298.65 Million | -0.308x | -216.86% |
| 2020-12-31 | $1.47 Billion | $387.04 Million | 0.263x | +143.97% |
| 2019-12-31 | $464.36 Million | $-278.01 Million | -0.599x | -43.34% |
| 2018-12-31 | $419.01 Million | $-175.01 Million | -0.418x | -117.42% |
| 2017-12-31 | $623.97 Million | $-119.86 Million | -0.192x | -66.98% |
| 2016-12-31 | $213.08 Million | $-24.51 Million | -0.115x | +47.71% |
| 2015-12-31 | $143.98 Million | $-31.68 Million | -0.220x | +77.98% |
| 2014-12-31 | $35.43 Million | $-35.40 Million | -0.999x | -107.86% |
| 2013-12-31 | $-1.50 Million | $-19.02 Million | 12.717x | -- |
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast … Read more